ClinicalTrials.gg
CompletedNCT03960866Updated Oct 30, 2026Results posted

Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma

A Phase 2 interventional study of Phentolamine Mesylate Ophthalmic Solution 1% and Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo) in Open Angle Glaucoma and Ocular Hypertension, sponsored by Opus Genetics, Inc. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Opus Genetics, Inc · Phase 2, Interventional, and Treatment

Updated Oct 30, 2026Sponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 348 studies in Glaucoma, Open-Angle with a site in United States — 49 open to participants now, 67 under way, 5 of them phase 3. Glaucoma, Open-Angle · United States.

Enrollment
207th of 279
39 · median 84
Started
2019
with 15 others
Phase 2
76 of 348
5 open now
Registered
215th of 348
by date

Among the 348 studies in Glaucoma, Open-Angle with a site in United States, this one is the 207th largest by enrollment of the 279 interventional ones that give a count, is one of 16 that started in 2019, is one of 76 in phase 2, and was the 215th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

49 of the 348 studies in Glaucoma, Open-Angle with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 348 studies in Glaucoma, Open-Angle with a site in United States, or all of them as a file.
02

Study summary

The objectives of this study are:

  • To evaluate the efficacy of Phentolamine Mesylate to lower intra-ocular pressure (IOP) in the treatment of Open-Angle Glaucoma (OAG) and Ocular Hypertension (OHT).
  • To evaluate the ocular and systemic safety of Phentolamine Mesylate compared to its vehicle.
  • To evaluate additional efficacy of Phentolamine Mesylate to improve visual performance.
Read the detailed description

Placebo-controlled double-masked, multiple dose Phase 2 study in 40 patients with IOP ≥ 22 and ≤30 mmHg, evaluating ocular and systemic safety and efficacy following administration of Phentolamine mesylate 1.0% QD at 8PM to 10PM in both eyes for 14 days.

03

Conditions studied

  • Open Angle Glaucoma
  • Ocular Hypertension

Keywords

  • Open Angle Glaucoma
  • Ocular Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years of age or greater
  2. Diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT). A reported history of untreated OHT with IOP ≥22mmHg and ≤ 30mmHg is preferred.
  3. Untreated or treated OAG/OHT with 2 or fewer ocular hypotensive medications.
  4. Untreated (post-washout) mean IOP ≥ 22mmHg and ≤30mmHg in the study eye at the Qualification Visit (8AM).
  5. Corrected visual acuity in each eye +1.0 logMAR or better by Early Treatment Diabetic Retinopathy Study (ETDRS) in each eye (equivalent to 20/200 or better) at the Screening Visit and Qualification Visit.
  6. Otherwise healthy and well-controlled subjects.
  7. Able and willing to give signed and follow study instructions.
  8. Able to self-administer study medication or to have study medication administered by a caregiver throughout the study period.

Exclusion criteria

Exclusion Criteria:

  1. Closed or very narrow angles (Grade 0-1, Shaffer)
  2. Glaucoma: pseudo-exfoliation or pigment dispersion component
  3. Known to any α-adrenoceptor antagonists
  4. Previous laser and/or non-laser glaucoma surgery or procedure in either eye
  5. Refractive surgery in either eye
  6. Ocular trauma in either eye within the 6 months prior to Screening, or ocular surgery or non-refractive laser treatment within the 3 months prior to Screening
  7. Recent or current evidence of ocular infection or inflammation in either eye
  8. Ocular medication in either eye of any kind within 30 days of Screening
  9. ocular disease in either eye
  10. History of diabetic retinopathy
  11. Contact lens wear within 3 days prior to and for the duration of the study
  12. Central corneal thickness in either eye >600 μm at Screening
  13. Any abnormality in either eye preventing reliable applanation tonometry
  14. Known hypersensitivity or to α- and/or β-adrenoceptor antagonists
  15. Clinically significant systemic disease that might interfere with the study
  16. Participation in any study within 30 days prior to Screening
  17. Use of any topical or systemic adrenergic or cholinergic drugs up to 30 days prior to Screening, or during the study
  18. Changes in systemic medication that could have an effect on IOP within 30 days prior to Screening
  19. Women of who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of
  20. Resting heart rate outside the normal range (50-110 beats per minute) at Screening or Qualification Visit
  21. Hypertension with resting diastolic blood pressure (BP) > 105 mmHg or systolic BP > 160 mmHg at the Screening or Qualification Visit
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Nyxol Ophthalmic Solution 1%

    1 drop in each eye daily (QD) at or before bedtime (8pm to 10pm) for 14 days

    Drug: Phentolamine Mesylate Ophthalmic Solution 1%

  • Placebo comparator
    Nyxol Ophthalmic Solution Vehicle

    1 drop in each eye daily (QD) at or before bedtime (8pm to 10pm) for 14 days

    Other: Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)

Interventions

06

What researchers measure

Primary outcomes

  1. Intraocular Pressure

    change from Baseline in mean diurnal IOP in the study eye

    Time frame: 15 days

Secondary outcomes

  1. Pupil Diameter

    Change from Baseline Pupil Diameter (Photopic Conditions)

    Time frame: 15 days

  2. Distance Visual Acuity

    Percentage of Subjects Achieving ≥1 line improvement in Distance Visual Acuity from Baseline measured at 4 meters (photopic conditions)

    Time frame: 15 days

  3. Conjunctival Hyperemia

    Conjunctival Hyperemia Category

    Time frame: 15 days

07

Results

Posted Jul 12, 2023

Participant flow

Participant flow — Overall Study
MilestoneNyxol Ophthalmic Solution 1%Nyxol Ophthalmic Solution Vehicle
Started1920
Completed1920
Not completed00

Outcome measures

PrimaryIntraocular Pressure

change from Baseline in mean diurnal IOP in the study eye

Time frame:
15 days
Reported as:
Mean · mmHg
Intraocular Pressure
mmHgNyxol Ophthalmic Solution 1%Nyxol Ophthalmic Solution Vehicle
Intraocular Pressure-2.30 ± 2.986-2.18 ± 1.856
Statistical analysis
  • Nyxol Ophthalmic Solution 1% vs Nyxol Ophthalmic Solution Vehicle · t-test, 2 sided · p = 0.89 · Mean difference (net): 0.12
SecondaryPupil Diameter

Change from Baseline Pupil Diameter (Photopic Conditions)

Time frame:
15 days
Reported as:
Mean · mm
Pupil Diameter
mmNyxol Ophthalmic Solution 1%Nyxol Ophthalmic Solution Vehicle
Day 8 (8AM)-0.77 ± 0.538-0.07 ± 0.555
Day 15 (8AM)-0.77 ± 0.550-0.01 ± 0.580
SecondaryDistance Visual Acuity

Percentage of Subjects Achieving ≥1 line improvement in Distance Visual Acuity from Baseline measured at 4 meters (photopic conditions)

Time frame:
15 days
Reported as:
Count of participants · Participants
Distance Visual Acuity
ParticipantsNyxol Ophthalmic Solution 1%Nyxol Ophthalmic Solution Vehicle
Distance Visual Acuity124
SecondaryConjunctival Hyperemia

Conjunctival Hyperemia Category

Time frame:
15 days
Reported as:
Count of participants · Participants
Conjunctival Hyperemia
ParticipantsNyxol Ophthalmic Solution 1%Nyxol Ophthalmic Solution Vehicle
None48
Mild108
Moderate34
Severe20

Adverse events

Collected over 14 Days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nyxol Ophthalmic Solution 1%0/19 (0%)0/19 (0%)5/19 (26.3%)
Nyxol Ophthalmic Solution Vehicle0/20 (0%)0/20 (0%)1/20 (5%)
Most frequent other events
Most frequent other events
EventNyxol Ophthalmic Solution 1%Nyxol Ophthalmic Solution Vehicle
Conjunctival HyperemiaEye disorders3/191/20
Installation Site DiscomfortGeneral disorders3/190/20
Eye PruritisEye disorders1/190/20

Baseline characteristics

Age, Continuous
Age, Continuous(years)Nyxol Ophthalmic Solution 1%Nyxol Ophthalmic Solution VehicleTotal
Mean58.1 ± 13.2363.2 ± 10.3560.7 ± 11.97
Sex: Female, Male
Sex: Female, Male(Participants)Nyxol Ophthalmic Solution 1%Nyxol Ophthalmic Solution VehicleTotal
Female91322
Male10717
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Nyxol Ophthalmic Solution 1%Nyxol Ophthalmic Solution VehicleTotal
White111425
Non-White8614
Baseline Intraocular Pressure (Study Eye)
Baseline Intraocular Pressure (Study Eye)(mmHg)Nyxol Ophthalmic Solution 1%Nyxol Ophthalmic Solution VehicleTotal
Mean23.43 ± 1.67524.38 ± 2.09723.92 ± 1.939
08

Study locations

5 sites
  • North Valley Eye Medical Group
    Mission Hills, California 91345, United States
  • Clayton Eye Clinical Research
    Morrow, Georgia 30260, United States
  • University of Michigan Kellogg Eye Center
    Ann Arbor, Michigan 48105, United States
  • Rochester Ophthalmological Group
    Rochester, New York 14618, United States
  • Abrams Eye Center
    Cleveland, Ohio 44115, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Sep 2019, 3 months.

Results were first posted in Jul 2023, 3 years 10 months after primary completion.

Of 38 industry-sponsored phase 2 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 16. This study's 3 months is below that.

Counting every sponsor, half of 41 studies reached it within 11 months; a quarter within 7 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2019
First posted
May 23, 2019
StartActual
May 28, 2019
Primary completionActual
Sep 11, 2019
CompletionActual
Sep 11, 2019
Results first posted
Jul 12, 2023
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sponsor
Ocuphire Pharma, Inc.→Opus Genetics, Inc
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Sponsor Ocuphire Pharma, Inc.→Opus Genetics, Inc
    + 3 other changes: identifiers, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03960866
Lead sponsor
Opus Genetics, Inc
Responsible party
Sponsor
First posted
May 23, 2019
Start date
May 28, 2019
Primary completion
Sep 11, 2019
Completion
Sep 11, 2019
Results posted
Jul 12, 2023
Last update
Oct 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Phentolamine

Start the discussion